2(R)-Benzyloxymethyl-3(S)-hydroxy tetrahydro-2H-pyran | 196406-94-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2(R)-Benzyloxymethyl-3(S)-hydroxy tetrahydro-2H-pyran
• 英文别名: (2R,3S)-2-(phenylmethoxymethyl)oxan-3-ol
• CAS: 196406-94-7
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: IHQWVMHFERPNKL-QWHCGFSZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2(R)-Benzyloxymethyl-3(S)-hydroxy tetrahydro-2H-pyran 在 palladium on activated charcoal 、 4-甲基苯磺酸吡啶 二苯基膦叠氮化物 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 25.0 ℃ 、405.3 kPa 条件下， 反应 36.0h， 生成 dl-methyl N-octadecylcarbamate
  参考文献：
  名称：

  Lactone and cyclic ether analogues of platelet-activating factor. Synthesis and biological activities.

  摘要：

  合成了六元内酯和四氢呋喃类的血小板激活因子（PAF）类似物4-11以及相关的拮抗衍生物41-46。没有发现δ-内酯4-7显示出PAF样活性，而对应的环醚8、9和11则表现出轻微活性。一些环状拮抗剂在抑制由于C16-PAF引起的血小板聚集（兔血小板富集血浆，IC50）和低血压（大鼠，DI50）方面的活性比开链拮抗剂CV-3988更强。例如，dl-3-{6-[O-(trans-3-十七烷基氨基甲酰氧基四氢呋喃-2-基)甲基]磷酸氧基}己基噻唑镁(内盐)(4ld)(IC50为5.5×10^-7M，ID50为0.046mg/kg，静脉注射)；dl-3-{5-[O-(cis-3-十七烷基氨基甲酰基硫四氢呋喃-2-基)甲基]磷酸氧基}戊基噻唑镁(内盐)(43c)(IC50为5.7×10^-7M，ID50为0.076mg/kg，静脉注射)。

  DOI：

  10.1248/cpb.37.2379
• 作为产物：
  描述：

  6-benzyloxymethyl-3,4-dihydro-2H-pyran 在 sodium hydroxide 、 dimethyl sulfide borane 、 双氧水 作用下， 生成 2(R)-Benzyloxymethyl-3(S)-hydroxy tetrahydro-2H-pyran
  参考文献：
  名称：

  Convergent Synthesis of a Trans-fused 6-7-6 Tricyclic Ether System Based on a Ring-closing Metathesis Reaction

  摘要：

  通过立体选择性缩醛形成、缩醛的还原裂解和环合关环反应，实现了一个反式融合的6-7-6三环醚体系的合成。

  DOI：

  10.1055/s-1997-969

文献信息

• HIV protease inhibitors useful for the treatment of aids
  申请人：MERCK & CO. INC.

  公开号：EP0534511A1

  公开（公告）日：1993-03-31

  Compounds of the form,         A-G-J    wherein A is an amine protecting group or urethane, G a dipeptide isostere and J a small terminal group are described. They are distinguished by tetrahydrofuryl or tetrahydropyranyl substituents, and the like. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  形式为A-G-J的化合物被描述，其中A是胺保护基或脲醚，G是二肽同分异构体，J是小的末端基团。它们以四氢呋喃基或四氢吡喃基取代等方式进行区分。这些化合物在抑制HIV蛋白酶、预防或治疗HIV感染以及治疗艾滋病方面具有用途，无论是作为化合物、药学上可接受的盐、药用组合成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
• Correlation between Conformational Equilibria of Free Host and Guest Binding Affinity in Non-preorganized Receptors
  作者：Romen Carrillo、Ezequiel Q. Morales、Víctor S. Martín、Tomás Martín

  DOI：10.1021/jo400683j

  日期：2013.8.16

  Positive cooperativity between host conformational equilibria and guest binding has been widely reported in protein receptors. However, reported examples of this kind of cooperativity in synthetic hosts are scarce and largely serendipitous, among other things because it is hard to envision systems which display this kind of cooperativity. In order to shed some light on the correlation between conformational equilibria of free host and guest binding, selected structural modifications have been performed over a family of nonpreorganized hosts in order to induce conformational changes and to analyze their effect on the binding affinity. The conformational effect was evaluated by a theoretical conformational search and correlated with the ability of the receptors. All data suggest that those receptors that display the best association constants are able to sample folded conformations analogous to the conformational requirements for the binding of the guests. On the contrary, for those receptors where folded conformers are scarce, then the association constant and enantioselectivity clearly drop.
• AZAINDAZOLES AS JAK2 INHIBITORS
  申请人：[en]AJAX THERAPEUTICS, INC.

  公开号：WO2024148247A2

  公开（公告）日：2024-07-11

  The present disclosure provides azaindazole compounds and compositions thereof useful for inhibiting JAK2.
• Lactone and cyclic ether analogues of platelet-activating factor. Synthesis and biological activities.
  作者：Hideki MIYAZAKI、Nobuyuki OHKAWA、Norio NAKAMURA、Tomiyoshi ITOU、Toshio SADA、Takeshi OSHIMA、Hiroyuki KOIKE

  DOI：10.1248/cpb.37.2379

  日期：——

  Six-membered lactone and tetrahydropyran analogues of platelet-activating factor (PAF), 4-11, and related antagonistic derivatives 41-46 were synthesized. None of the δ-lactones 4-7 showed PAF-like activities, while the corresponding cyclic ethers 8, 9 and 11 were slightly active. Some of the cyclic antagonists showed more potent inhibitory activities than the open chain antagonist CV-3988 against platelet aggregation (rabbit platelet-rich plasma, IC50) and hypotension (rat, DI50) induced by C16-PAF : e.g. dl-3-6-[O-(trans-3-heptadeclcarbamoyloxytetrahydropyran-2-yl)methyl]phosphonoxy}hexylthiazolium (inner salt)(4ld)(IC505.5×10-7M, ID500.046mg/kg, i.v.);dl-3-5-[O-(cis-3-heptadecylcarbamoylthiotetrahydropyran-2-yl)methyl]phosphonoxy}pentylthiazolium (inner salt) (43c) (IC505.7×10-7M, ID500.076mg/kg, i.v.).

  合成了六元内酯和四氢呋喃类的血小板激活因子（PAF）类似物4-11以及相关的拮抗衍生物41-46。没有发现δ-内酯4-7显示出PAF样活性，而对应的环醚8、9和11则表现出轻微活性。一些环状拮抗剂在抑制由于C16-PAF引起的血小板聚集（兔血小板富集血浆，IC50）和低血压（大鼠，DI50）方面的活性比开链拮抗剂CV-3988更强。例如，dl-3-6-[O-(trans-3-十七烷基氨基甲酰氧基四氢呋喃-2-基)甲基]磷酸氧基}己基噻唑镁(内盐)(4ld)(IC50为5.5×10^-7M，ID50为0.046mg/kg，静脉注射)；dl-3-5-[O-(cis-3-十七烷基氨基甲酰基硫四氢呋喃-2-基)甲基]磷酸氧基}戊基噻唑镁(内盐)(43c)(IC50为5.7×10^-7M，ID50为0.076mg/kg，静脉注射)。
• Convergent Synthesis of a <i>Trans</i>-fused 6-7-6 Tricyclic Ether System Based on a Ring-closing Metathesis Reaction
  作者：Tohru Oishi、Yoko Nagumo、Masahiro Hirama

  DOI：10.1055/s-1997-969

  日期：1997.8

  Synthesis of a trans-fused 6-7-6 tricyclic ether system was achieved via stereoselective acetal formation, reductive cleavage of the acetal, and a ring-closing metathesis reaction.

  通过立体选择性缩醛形成、缩醛的还原裂解和环合关环反应，实现了一个反式融合的6-7-6三环醚体系的合成。